{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:13:20Z","timestamp":1773306800471,"version":"3.50.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.pharep.2014.05.003","type":"journal-article","created":{"date-parts":[[2014,5,23]],"date-time":"2014-05-23T01:45:23Z","timestamp":1400809523000},"page":"811-820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The latest achievements in the pharmacotherapy of gambling disorder"],"prefix":"10.1007","volume":"66","author":[{"given":"Krzysztof","family":"\u0141abuzek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Beil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Beil-Gawe\u0142czyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo\u017cena","family":"Gabryel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Franik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bogus\u0142aw","family":"Okopie\u0144","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"10.1016\/j.pharep.2014.05.003_bib0005","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.pharep.2014.05.003_bib0010","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2000"},{"issue":"12","key":"10.1016\/j.pharep.2014.05.003_bib0015","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4088\/JCP.v62n1207","article-title":"Demographic and clinical characteristics of 131 adult pathological gamblers","volume":"62","author":"Grant","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.pharep.2014.05.003_bib0020","first-page":"81","article-title":"Problem gambling in Europe: what do we know?","volume":"6","author":"Griffiths","year":"2010","journal-title":"Casino Gaming Int"},{"key":"10.1016\/j.pharep.2014.05.003_bib0025","first-page":"CD008937","article-title":"Psychological therapies for pathological and problem gambling","volume":"11","author":"Cowlishaw","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.pharep.2014.05.003_bib0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3928\/0279-3695-20020301-12","article-title":"Pathological gambling. Identification and treatment","volume":"40","author":"Ozga","year":"2002","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"issue":"1","key":"10.1016\/j.pharep.2014.05.003_bib0035","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2174\/2211556011201010067","article-title":"Pathological gambling: neuropsychopharmacology and treatment","volume":"1","author":"Bullock","year":"2012","journal-title":"Curr Psychopharmacol"},{"issue":"3","key":"10.1016\/j.pharep.2014.05.003_bib0040","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3109\/10673229.2012.694318","article-title":"Pathological gambling: a systematic review of biochemical, neuroimaging, and neuropsychological findings","volume":"20","author":"Conversano","year":"2012","journal-title":"Harv Rev Psychiatry"},{"issue":"1","key":"10.1016\/j.pharep.2014.05.003_bib0045","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10899-004-1932-8","article-title":"Pharmacological treatments of pathological gambling","volume":"21","author":"Hollander","year":"2005","journal-title":"J Gambl Stud"},{"issue":"11","key":"10.1016\/j.pharep.2014.05.003_bib0050","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1093\/aje\/kwr017","article-title":"Disordered (pathologic or problem) gambling and axis I psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"173","author":"Chou","year":"2011","journal-title":"Am J Epidemiol"},{"issue":"3","key":"10.1016\/j.pharep.2014.05.003_bib0055","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10899-005-3099-3","article-title":"The association between comorbidity and outcome in pathological gambling: a prospective follow-up of recentquitters","volume":"21","author":"Hodgins","year":"2005","journal-title":"J Gambl Stud"},{"issue":"5968","key":"10.1016\/j.pharep.2014.05.003_bib0060","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1126\/science.327.5968.935","article-title":"Behavioral addictions debut in proposed DSM-V","volume":"327","author":"Holden","year":"2010","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.pharep.2014.05.003_bib0065","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0006-3223(00)00888-X","article-title":"Casino gambling increases heart rate and salivary cortisol in regular gamblers","volume":"48","author":"Meyer","year":"2000","journal-title":"Biol Psychiatry"},{"issue":"4","key":"10.1016\/j.pharep.2014.05.003_bib0070","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1001\/archpsyc.1988.01800280085011","article-title":"Pathological gambling. A psychobiological study","volume":"45","author":"Roy","year":"1988","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"10.1016\/j.pharep.2014.05.003_bib0075","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1159\/000089004","article-title":"Cortisol and heart rate measures during casino gambling in relation to impulsivity","volume":"52","author":"Krueger","year":"2005","journal-title":"Neuropsychobiology"},{"issue":"12","key":"10.1016\/j.pharep.2014.05.003_bib0080","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1017\/S1092852900006799","article-title":"Altered CSF 5-HIAA disposition in pathologic male gamblers","volume":"4","author":"Nordin","year":"1999","journal-title":"CNS Spectr"},{"issue":"12","key":"10.1016\/j.pharep.2014.05.003_bib0085","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1177\/0269881109106907","article-title":"Serotonin function in pathological gambling: blunted growth hormone response to sumatriptan","volume":"24","author":"Pallanti","year":"2010","journal-title":"J Psychopharmacol"},{"issue":"8","key":"10.1016\/j.pharep.2014.05.003_bib0090","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.biopsych.2006.08.029","article-title":"Diplotypes of the human serotonin 1B receptor promoter predict growth hormone responses to sumatriptan in abstinent alcohol-dependent men","volume":"61","author":"Moss","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"12","key":"10.1016\/j.pharep.2014.05.003_bib0095","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1017\/S1092852900015145","article-title":"Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo","volume":"11","author":"Pallanti","year":"2006","journal-title":"CNS Spectr"},{"issue":"1\u20133","key":"10.1016\/j.pharep.2014.05.003_bib0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0014-2999(00)00544-6","article-title":"Endogenous opioids and reward","volume":"405","author":"Van Ree","year":"2000","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"10.1016\/j.pharep.2014.05.003_bib0105","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1001\/archpsyc.1992.01820110040006","article-title":"Naltrexone in the treatment of alcohol dependence","volume":"49","author":"Volpicelli","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.pharep.2014.05.003_bib0110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2114\/jpa.18.37","article-title":"Physiological changes in Pachinko players; beta-endorphin, catecholamines, immune system substances and heart rate","volume":"18","author":"Shinohara","year":"1999","journal-title":"Appl Human Sci"},{"key":"10.1016\/j.pharep.2014.05.003_bib0115","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3389\/fncir.2013.00152","article-title":"Dopamine signaling in reward-related behaviors","volume":"7","author":"Baik","year":"2013","journal-title":"Front Neural Circuits"},{"issue":"2","key":"10.1016\/j.pharep.2014.05.003_bib0120","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1124\/pr.109.001933","article-title":"Drug wanting: behavioral sensitization and relapse to drug-seeking behavior","volume":"63","author":"Steketee","year":"2011","journal-title":"Pharmacol Rev"},{"issue":"4","key":"10.1016\/j.pharep.2014.05.003_bib0125","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.pbb.2011.04.015","article-title":"Glutamatergic medications for the treatment of drug and behavioral addictions","volume":"100","author":"Olive","year":"2012","journal-title":"Pharmacol Biochem Behav"},{"issue":"5\u20136","key":"10.1016\/j.pharep.2014.05.003_bib0130","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/FBP.0b013e32833d41b2","article-title":"Using glutamate homeostasis as a target for treating addictive disorders","volume":"21","author":"Reissner","year":"2010","journal-title":"Behav Pharmacol"},{"issue":"4","key":"10.1016\/j.pharep.2014.05.003_bib0135","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/sj.mp.4001269","article-title":"Glutamatergic mechanisms in addiction","volume":"8","author":"Tzschentke","year":"2003","journal-title":"Mol Psychiatry"},{"issue":"3","key":"10.1016\/j.pharep.2014.05.003_bib0140","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/YCO.0b013e3283386578","article-title":"Long-acting depot formulations of naltrexone for heroin dependence: a review","volume":"23","author":"Krupitsky","year":"2010","journal-title":"Curr Opin Psychiatry"},{"issue":"5","key":"10.1016\/j.pharep.2014.05.003_bib0145","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00004850-200109000-00006","article-title":"An open naltrexone treatment study in pathological gambling disorder","volume":"16","author":"Kim","year":"2001","journal-title":"Int Clin Psychopharmacol."},{"issue":"5","key":"10.1016\/j.pharep.2014.05.003_bib0150","first-page":"783","article-title":"A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges","volume":"69","author":"Grant","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.pharep.2014.05.003_bib0155","first-page":"35","article-title":"Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: a pilot study","volume":"43","author":"Lahti","year":"2010","journal-title":"Psychopharmacol Bull"},{"issue":"11","key":"10.1016\/j.pharep.2014.05.003_bib0160","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1111\/j.1360-0443.2008.02345.x","article-title":"Persistence with oral naltrexone for alcohol treatment: implications for healthcare-utilization","volume":"103","author":"Kranzler","year":"2008","journal-title":"Addiction"},{"issue":"11","key":"10.1016\/j.pharep.2014.05.003_bib0165","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0006-3223(01)01079-4","article-title":"Double blind naltrexone and placebo comparison study in the treatment of pathological gambling","volume":"49","author":"Kim","year":"2001","journal-title":"Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.pharep.2014.05.003_bib0170","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/j.1530-0277.2007.00593.x","article-title":"Hepatic safety of once-monthly injectable extended-release naltrexone administered to actively drinking alcoholics","volume":"32","author":"Lucey","year":"2008","journal-title":"Alcohol Clin Exp Res"},{"issue":"2","key":"10.1016\/j.pharep.2014.05.003_bib0175","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.alcohol.2006.05.003","article-title":"Study of hepatotoxicity of naltrexone in the treatment of alcoholism","volume":"38","author":"Yen","year":"2006","journal-title":"Alcohol."},{"issue":"2","key":"10.1016\/j.pharep.2014.05.003_bib0180","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00002826-200603000-00004","article-title":"Safety of high-dose naltrexone treatment: hepatic transaminase profiles among outpatients","volume":"29","author":"Kim","year":"2006","journal-title":"Clin Neuropharmacol"},{"issue":"9","key":"10.1016\/j.pharep.2014.05.003_bib0185","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40263-013-0101-y","article-title":"Nalmefene: a review of its use in the treatment of alcohol dependence","volume":"27","author":"Keating","year":"2013","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.pharep.2014.05.003_bib0190","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1176\/appi.ajp.163.2.303","article-title":"Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling","volume":"163","author":"Grant","year":"2006","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.pharep.2014.05.003_bib0195","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1192\/bjp.bp.110.078105","article-title":"Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study","volume":"197","author":"Grant","year":"2010","journal-title":"Br J Psychiatry"},{"issue":"2","key":"10.1016\/j.pharep.2014.05.003_bib0200","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2165\/00023210-200822020-00004","article-title":"Pathological gambling: an update on neuropathophysiology and pharmacotherapy","volume":"22","author":"Iancu","year":"2008","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.pharep.2014.05.003_bib0205","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4088\/JCP.v63n0704","article-title":"Lithium and valproate treatment of pathological gambling: a randomized single-blind study","volume":"63","author":"Pallanti","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"10.1016\/j.pharep.2014.05.003_bib0210","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1176\/appi.ajp.162.1.137","article-title":"Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders?","volume":"162","author":"Hollander","year":"2005","journal-title":"Am J Psychiatry"},{"issue":"5","key":"10.1016\/j.pharep.2014.05.003_bib0215","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1016\/j.pnpbp.2008.02.013","article-title":"Extended release carbamazepine in the treatment of pathological gambling: an open-label study","volume":"32","author":"Black","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"10.1016\/j.pharep.2014.05.003_bib0220","doi-asserted-by":"crossref","first-page":"433","DOI":"10.4088\/JCP.v69n0314","article-title":"Olanzapine in the treatment of pathological gambling: a negative randomized placebo-controlled trial","volume":"69","author":"McElroy","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.pharep.2014.05.003_bib0225","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.pbb.2007.12.025","article-title":"A double-blind, placebo-controlled trial of olanzapine for the treatment of video poker pathological gamblers","volume":"89","author":"Fong","year":"2008","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"10.1016\/j.pharep.2014.05.003_bib0230","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/00004850-200307000-00007","article-title":"Paroxetine treatment of pathological gambling: a multi-centre randomized controlled trial","volume":"18","author":"Grant","year":"2003","journal-title":"Int Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.pharep.2014.05.003_bib0235","doi-asserted-by":"crossref","first-page":"501","DOI":"10.4088\/JCP.v63n0606","article-title":"A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling","volume":"63","author":"Kim","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.pharep.2014.05.003_bib0240","first-page":"289","article-title":"Fluvoxamine in the treatment of anxiety disorders","volume":"1","author":"Irons","year":"2005","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"10.1016\/j.pharep.2014.05.003_bib0245","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3109\/10401230209147393","article-title":"A pilot placebo-controlled study of fluvoxamine for pathological gambling","volume":"14","author":"Blanco","year":"2002","journal-title":"Ann Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.pharep.2014.05.003_bib0250","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0006-3223(00)00241-9","article-title":"A randomized double-blind fluvoxamine\/placebo crossover trial in pathologic gambling","volume":"47","author":"Hollander","year":"2000","journal-title":"Biol Psychiatry"},{"issue":"12","key":"10.1016\/j.pharep.2014.05.003_bib0255","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1176\/ajp.155.12.1781","article-title":"Short-term single-blind fluvoxamine treatment of pathological gambling","volume":"155","author":"Hollander","year":"1998","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.pharep.2014.05.003_bib0260","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4088\/JCP.v63n0109","article-title":"An open-label study of citalopram in the treatment of pathological gambling","volume":"63","author":"Zimmerman","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.pharep.2014.05.003_bib0265","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.encep.2008.04.004","article-title":"Efficacy and tolerability of escitalopram in anxiety disorders: a review","volume":"34","author":"Pelissolo","year":"2008","journal-title":"Encephale"},{"issue":"4","key":"10.1016\/j.pharep.2014.05.003_bib0270","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/wnf.0b013e31803d357f","article-title":"An open-label trial of escitalopram in the treatment of pathological gambling","volume":"30","author":"Black","year":"2007","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"10.1016\/j.pharep.2014.05.003_bib0275","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00004850-200607000-00002","article-title":"Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation","volume":"21","author":"Grant","year":"2006","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.pharep.2014.05.003_bib0280","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4088\/JCP.v66n0104","article-title":"Sertraline treatment of pathological gambling: a pilot study","volume":"66","author":"Saiz-Ruiz","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.pharep.2014.05.003_bib0285","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/01.jcp.0000126666.83068.a9","article-title":"Improvement of pathologic gambling symptoms after administration of sertraline: a case report","volume":"24","author":"Meroni","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"10.1016\/j.pharep.2014.05.003_bib0290","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.2042-7158.1970.tb08487.x","article-title":"On the mode of action of amantadine","volume":"22","author":"Stromberg","year":"1970","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.pharep.2014.05.003_bib0295","first-page":"251","article-title":"Renaissance of amantadine in the treatment of Parkinson's disease","volume":"91","author":"Blanchet","year":"2003","journal-title":"Adv Neurol"},{"issue":"3","key":"10.1016\/j.pharep.2014.05.003_bib0300","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/ana.22029","article-title":"Pathological gambling in Parkinson disease is reduced by amantadine","volume":"68","author":"Thomas","year":"2010","journal-title":"Ann Neurol"},{"issue":"8","key":"10.1016\/j.pharep.2014.05.003_bib0305","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2165\/11634390-000000000-00000","article-title":"The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence","volume":"26","author":"Sani","year":"2012","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.pharep.2014.05.003_bib0310","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/cercor\/bhp145","article-title":"A 1H-MR spectroscopy study of changes in glutamate and glutamine (Glx) concentrations in frontal spectra after administration of memantine","volume":"20","author":"Van Wageningen","year":"2010","journal-title":"Cereb Cortex"},{"issue":"4","key":"10.1016\/j.pharep.2014.05.003_bib0315","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00213-010-1994-5","article-title":"Memantine shows promise in reducing gambling severity and cognitive inflexibility in pathological gambling: a pilot study","volume":"212","author":"Grant","year":"2010","journal-title":"Psychopharmacology (Berl)"},{"issue":"6","key":"10.1016\/j.pharep.2014.05.003_bib0320","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/j.1471-4159.2005.03517.x","article-title":"Cocaine-induced alterations in nucleus accumbens ionotropic glutamate receptor subunits in human and non-human primates","volume":"95","author":"Hemby","year":"2005","journal-title":"J Neurochem"},{"issue":"6","key":"10.1016\/j.pharep.2014.05.003_bib0325","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.biopsych.2006.11.021","article-title":"N-acetylcysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study","volume":"62","author":"Grant","year":"2007","journal-title":"Biol Psychiatry"},{"issue":"1","key":"10.1016\/j.pharep.2014.05.003_bib0330","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4088\/JCP.13m08411","article-title":"A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers","volume":"75","author":"Grant","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"10.1016\/j.pharep.2014.05.003_bib0335","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.euroneuro.2012.10.004","article-title":"Effect of modafinil on impulsivity and relapse in alcohol dependent patients: a randomized, placebo-controlled trial","volume":"23","author":"Joos","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"6","key":"10.1016\/j.pharep.2014.05.003_bib0340","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1177\/0269881108091072","article-title":"Effects of the atypical stimulant modafinil on a brief gambling episode in pathological gamblers with high vs. low impulsivity","volume":"23","author":"Zack","year":"2009","journal-title":"J Psychopharmacol"},{"issue":"7","key":"10.1016\/j.pharep.2014.05.003_bib0345","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1440-1819.2011.02264.x","article-title":"Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials","volume":"65","author":"Maneeton","year":"2011","journal-title":"Psychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.pharep.2014.05.003_bib0350","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/01.jcp.0000114844.58996.4a","article-title":"An open-label trial of bupropion in the treatment of pathologic gambling","volume":"24","author":"Black","year":"2004","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.pharep.2014.05.003_bib0355","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/01.jcp.0000264985.25109.25","article-title":"Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study","volume":"27","author":"Black","year":"2007","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"10.1016\/j.pharep.2014.05.003_bib0360","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1742-1241.2006.01065.x","article-title":"Baclofen: a new drug for the treatment of alcohol dependence","volume":"60","author":"Addolorato","year":"2006","journal-title":"Int J Clin Pract"},{"issue":"6","key":"10.1016\/j.pharep.2014.05.003_bib0365","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.clinthera.2005.06.015","article-title":"Acamprosate for the treatment of alcohol dependence","volume":"27","author":"Boothby","year":"2005","journal-title":"Clin Ther"},{"key":"10.1016\/j.pharep.2014.05.003_bib0370","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3389\/fpsyt.2011.00033","article-title":"Acamprosate and baclofen were not effective in the treatment of pathological gambling: preliminary blind rater comparison study","volume":"2","author":"Dannon","year":"2011","journal-title":"Front Psychiatry"},{"issue":"4","key":"10.1016\/j.pharep.2014.05.003_bib0375","first-page":"250","article-title":"An open-label trial of acamprosate in the treatment of pathological gambling","volume":"23","author":"Black","year":"2011","journal-title":"Ann Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.pharep.2014.05.003_bib0380","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/jcp.0b013e31815a4400","article-title":"12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study","volume":"27","author":"Dannon","year":"2007","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.pharep.2014.05.003_bib0385","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/WNF.0b013e31828740ea","article-title":"Four-year follow-up study of pharmacological treatment in pathological gamblers","volume":"36","author":"Rosenberg","year":"2013","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"10.1016\/j.pharep.2014.05.003_bib0390","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/jcp.013e3180dcc304d","article-title":"Outcome of pharmacological treatments of pathological gambling: a review and meta-analysis","volume":"27","author":"Pallesen","year":"2007","journal-title":"J Clin Psychopharmacol"},{"issue":"8","key":"10.1016\/j.pharep.2014.05.003_bib0395","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1586\/14737175.2013.814938","article-title":"Meta-analysis: pharmacological treatment of pathological gambling","volume":"13","author":"Bartley","year":"2013","journal-title":"Expert Rev Neurother"},{"issue":"6","key":"10.1016\/j.pharep.2014.05.003_bib0400","doi-asserted-by":"crossref","first-page":"334","DOI":"10.4088\/PCC.v08n0603","article-title":"Pathological gambling: a review of phenomenological models and treatment modalities for an underrecognized psychiatric disorder","volume":"8","author":"Dannon","year":"2006","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.pharep.2014.05.003_bib0405","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1034\/j.1600-0447.2003.00162.x","article-title":"Comorbidity of impulse control disorders in pathological gamblers","volume":"108","author":"Grant","year":"2003","journal-title":"Acta Psychiatr Scand"},{"issue":"5","key":"10.1016\/j.pharep.2014.05.003_bib0410","doi-asserted-by":"crossref","first-page":"564","DOI":"10.4088\/JCP.v66n0504","article-title":"Comorbidity of DSM-IV pathological gambling and other psychiatric disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"66","author":"Petry","year":"2005","journal-title":"J Clin Psychiatry"},{"issue":"6","key":"10.1016\/j.pharep.2014.05.003_bib0415","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.jcp.0000186867.90289.ed","article-title":"Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study","volume":"25","author":"Dannon","year":"2005","journal-title":"J Clin Psychopharmacol"},{"issue":"Suppl. 4","key":"10.1016\/j.pharep.2014.05.003_bib0420","first-page":"3","article-title":"Obsessive-compulsive spectrum disorders","volume":"56","author":"Hollander","year":"1995","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.pharep.2014.05.003_bib0425","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.eurpsy.2004.04.012","article-title":"Comorbid psychiatric diagnoses in kleptomania and pathological gambling: a preliminary comparison study","volume":"19","author":"Dannon","year":"2004","journal-title":"Eur Psychiatry"},{"issue":"2","key":"10.1016\/j.pharep.2014.05.003_bib0430","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10899-010-9211-3","article-title":"Gambling behavior among adolescents with attention deficit\/hyperactivity disorder","volume":"27","author":"Faregh","year":"2011","journal-title":"J Gambl Stud"},{"issue":"4","key":"10.1016\/j.pharep.2014.05.003_bib0435","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1212\/CPJ.0b013e318278be9b","article-title":"Impulse control disorders and compulsive behaviors associated with dopaminergic therapies in Parkinson disease","volume":"2","author":"Weiss","year":"2012","journal-title":"Neurol Clin Pract"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014001996?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114014001996?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:35:31Z","timestamp":1752611731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2014.05.003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":87,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S1734114014001996"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2014.05.003","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The latest achievements in the pharmacotherapy of gambling disorder","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2014.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}